Cultivating Growth
The life sciences will continue to have a far-reaching impact on virtually every aspect of our society. Safeguard partners with companies that recognize the pervasive power of life sciences, and seek to harness its opportunities for long-lasting value.
We seek opportunities to partner with entrepreneurs addressing the life sciences industry’s pressing needs. As our population ages, demand increases for effective and value-oriented healthcare products and services. The industry demands innovative ways to enhance drug development pipelines, comply with regulatory requirements and increase efficiencies throughout the process. Diagnostics, devices and drugs are converging in increasingly targeted treatments. And, while patient outcomes are improving, the entire industry is under pressure to curb escalating healthcare expenditures.
From the complex process of drug discovery in the lab to the diagnosis and treatment of disease, Safeguard partner companies seize the opportunities that these trends create. We are proactively targeting selected markets to bring Safeguard together with these exciting entrepreneurs.
Advanced BioHealing, Inc.
Advanced BioHealing (ABH) is a specialty biotechnology company focused on the development and marketing of cell-based and tissue-engineered products for wound care. Learn more >>
Alverix, Inc.
Alverix developes proprietary point-of-care technologies for low-cost, handheld reader devices with the accuracy and precision of laboratory instrumentation. Current applications include drugs of abuse (DOA), cardiac, cancer, infectious diseases and drug efficacy. Learn more >>
Avid Radiopharmaceuticals, Inc.
Avid Radiopharmaceuticals, Inc. is developing novel diagnostic imaging agents to enable earlier and more accurate diagnosis, treatment selection and therapeutic monitoring of major medical disorders. Learn more >>
Cellumen, Inc.
Cellumen delivers proprietary services and products to support drug discovery and development. By leveraging cellular systems biology, Cellumen’s objective is to improve the efficacy, decrease the toxicity, and optimize patient stratification and treatment for pharmaceutical companies’ new and existing drugs.
Learn more >>
Clarient, Inc.
Clarient (Nasdaq: CLRT) is a comprehensive cancer diagnostics company combining innovative technologies with expertise to assess and characterize cancer. Learn more >>
Molecular Biometrics, Inc.
is applying novel metabolomic technologies to develop accurate, non-invasive clinical tools for use in personalized medicine to evaluate normal biologic function in health and in disease, and for drug discovery and development. Learn more >>
NuPathe, Inc.
NuPathe specializes in the development of therapeutics for the treatment of neurological and psychiatric disorders including migraine, Parkinson’s disease
and schizophrenia. Learn more >>
Rubicor Medical, Inc.
Rubicor Medical develops and distributes technologically advanced, disposable, breast biopsy devices. Learn more >>
Tengion, Inc.
Tengion is a clinical stage regenerative medicine company that focuses on developing, manufacturing and commercializing human neo-organs and neo-tissues using its Autologous Organ Regeneration Platform™. Learn more >>